login
Become a member
Quick Registration
Full Registration Benefits -
Free Homepages for Doctors
Free Homepages for Hospitals
Free Homepages for Medical Conference
Free Homepages for NGO's
Personal Health Record Creation
Access to all Medical Slides
Access to all Jobs & Products Sale
Intercell to Begin Phase II JE Vaccine Trials in India
April 06, 2007 at 11:51 AM
Drug News
The randomized and controlled study aims to demonstrate the dose, safety and immunogenicity of Intercell’s JE vaccine compared to a locally produced mouse-brain Japanese Encephalitis vaccine.
The study, which will start in late April/early May, will enroll children at the age of one to three years. It is the first step towards the licensure of a new cell culture derived product in Asia, which is expected for late 2008/early 2009.
Mr Gerd Zettlmeissl, Chief Executive Officer of Intercell, said, “We have clearly defined a straight forward development process for our Japanese Encephalitis vaccine to enter endemic markets. It is our priority to make the vaccine, which is based on proven and safe technology, also available for the population and especially the children in endemic regions.”
Mr Vijay Kumar Datla, Chairman and Managing Director of Biological E. Ltd said, "We believe that this is a very important milestone in our endeavor to bring a safe and efficacious vaccine to endemic regions."
Source: BioSpectrum
SRM/M
|
|
More News on: Genital Herpes
 Comment & Contribute
|
Medwonders Health Network
- Health News Index
- News Quick Links
| News Categories: |
| » | Research: Bright Colored Chips can Cut Consumption by Half |
| » | Olympic Athlete's Body Via the 80-10-10 Raw Vegan Diet |
| » | Importance of Canned Foods To Help Tackle IOM Weight Of The Nation Recommendations, Highlights Study |
| » | US Rules Pomegranate Juice Claims Deceptive |
| » | Reducing Entrée Size Could Increase Fruit and Vegetable Intake in Children |
| More Diet News | |
|
